Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunny PharmtechROCO:6676 61 Days Payable is 30.40 as of Dec. 2025, which is 31% below its 10-year median of 44.09. GuruFocus rates ROCO:6676 with a GF Score™ of 61/100 and a GF Value™ of NT$13.45 (Fairly Valued). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Sunny Pharmtech ranks worse than 75.18% on this metric.
The historical rank and industry rank for Sunny Pharmtech's Days Payable or its related term are showing as below:
ROCO:6676'
s Days Payable Range Over the Past 10 Years
Min: 25.52 Med: 44.09 Max: 57.93
Current: 38.26
During the past 8 years, Sunny Pharmtech's highest Days Payable was 57.93. The lowest was 25.52. And the median was 44.09.
ROCO:6676's Days Payable is ranked worse than 75.18% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6676: 38.26
Sunny Pharmtech's Days Payable
declined
from Dec. 2024 (39.18) to Dec. 2025 (30.40).
It may suggest that Sunny Pharmtechaccelerated paying its suppliers.
Sunny Pharmtech Days Payable Related Terms
Sunny Pharmtech Days Payable Historical Data
* Premium members only.
The historical data trend for Sunny Pharmtech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6676 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Sunny Pharmtech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunny Pharmtech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunny Pharmtech's Days Payable distribution charts can be found below:
* The bar in red indicates where Sunny Pharmtech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sunny Pharmtech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunny Pharmtech (ROCO:6676) has a Days Payable of 30.40 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sunny Pharmtech and its competitors. This is 31% below median its historical median of 44.09. Over the past decade, Sunny Pharmtech's Days Payable has ranged from 25.52 to 57.93. According to the industry distribution chart, Sunny Pharmtech ranks #527 out of 701 companies in the Biotechnology industry, placing it in the top 75.2%.
Is Sunny Pharmtech's Days Payable too high?
Sunny Pharmtech's current Days Payable of 30.40 is 31% below median its 10-year median of 44.09. Over the past 10 years, this metric has ranged from a low of 25.52 to a high of 57.93. The Biotechnology industry median Days Payable is 112.84. Sunny Pharmtech's value of 30.40 is 73.1% below this industry median. Based on the distribution chart, Sunny Pharmtech ranks #527 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sunny Pharmtech has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sunny Pharmtech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunny Pharmtech ranks #527 out of 701 companies for Days Payable. This places Sunny Pharmtech in the lower half of its industry. The industry median Days Payable is 112.84. Sunny Pharmtech's value of 30.40 is 73.1% below this benchmark. Historically, Sunny Pharmtech's own Days Payable has ranged from 25.52 to 57.93 over the past decade. While the company's 10-year median is 44.09 vs. the industry median of 112.84, Sunny Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunny Pharmtech's current Days Payable of 30.40 is 73.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sunny Pharmtech and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunny Pharmtech's current Days Payable is 30.40, which is 31% below median its own 10-year median of 44.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunny Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sunny Pharmtech (ROCO:6676) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.45, compared to a current price of NT$13.40 — trading 0.4% below its estimated fair value. The current Days Payable is 30.40, which is 31% below median its 10-year median of 44.09 and 73.1% below the Biotechnology industry median of 112.84. Sunny Pharmtech's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sunny Pharmtech (ROCO:6676), the current Days Payable is 30.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunny Pharmtech (ROCO:6676) Overvalued in 2026?
Based on GuruFocus' analysis, Sunny Pharmtech stock appears to be undervalued.
The current stock price of NT$13.40 is trading 0.4% below its estimated GF Value™ of NT$13.45.
GuruFocus considers Sunny Pharmtech to be Fairly Valued.
Key valuation signals for ROCO:6676:
Days Payable: 30.40 (31% below median its 10-year median of 44.09)
GF Value™: NT$13.45 vs. price of NT$13.40 (0.4% below fair value)
Industry Position: 73.1% below the Biotechnology median (#527 of 701)
No single metric tells the full story. See the ROCO:6676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.
61GF Score
Get the complete analysis for ROCO:6676
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6676 has been successfully added to your 
